Reduction of alcohol consumption in alcohol-dependent patients?: Results of new phase-II studies with the opioid modulator nalmefene;Trinkmengenreduktion bei Alkoholabhängigen?: Ergebnisse neuer Phase-III-Studien mit dem Opiatmodulator Nalmefen

Suchttherapie

Volumn 15, Issue 4, 2014, Pages 174-178

  Mann, K ^a,b  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

abstinence; alcohol dependence; general practitioner; nalmefene; reduction

Indexed keywords

EID: 84910115406     PISSN: 14399903     EISSN: 1439989X     Source Type: Journal    
DOI: 10.1055/s-0034-1390485     Document Type: Article

References (27)

1. Pabst A., Kraus L., Gomes de Matos E. et al. Substanzkonsum und substanzbezogene Störungen in Deutschland im Jahr 2012. Sucht: 2013; 59 321 331
2. Wienberg G. Versorgungsstrukturen von Menschen mit Alkoholproblemen in Deutschland - eine Analyse aus Public Health-Perspektive. In: Mann K. editor. Neue Therapieansätze bei Alkoholproblemen. Lengerich Pabst: 2002; 17 46
3. Lim S. S., Vos T., Flaxman A. D. et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380 2224 2260
4. Kohn R., Saxena S., Levav I. et al. The treatment gap in mental health care. Bull World Health Org: 2004; 82 858 866
5. Rehm J., Rehm M., Shield K. D. et al. Reduzierung alkoholbedingter Mortalität durch Behandlung der Alkoholabhängigkeit. Sucht: 2014; 60 93 105
6. Mann K., Körkel J. Trinkmengenreduktion: ein ergänzendes Therapieziel bei Alkoholabhängigen? Psychopharmakotherapie: 2013; 5 193 198
7. Rosenberg H., Melville J. Levell Det al. A 10-year follow-up survey of acceptability of controlled drinking in Britain. J Stud Alcohol.: 1992; 53 441 446
8. Witkiewitz K. Lapses following alcohol treatment: modeling the falls from the wagon. J Stud Alcohol Drugs: 2008; 69 594 604
9. Kline-Simon A. H., Falk D. E., Litten R. Z. et al. Posttreatment low-risk drinking as a predictor of future drinking and problem outcomes among individuals with alcohol use disorders. Alcohol Clin Exp Res: 2013; 37 (Suppl 1) E373 E80
10. European Medicines Agency (EMEA) Guideline on the development of medicinal products for the treatment of alcohol dependence. EMEA/CHMP/EWP/20097/2008: 2010
11. European Medicines Agency - Find medicine - Selincro Available at http://www.ema.europa.eu/ema/index.jsp?Curl=pages/medicines/human/medicines/002583/human-med-001620.jsp&mid=WC0b01ac058001d124 (4 April 2013, date last accessed)
12. Bart G., Schluger J. H., Borg L. et al. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology: 2005; 30 2254 2262
13. Mason B. J., Ritvo E. C., Morgan RO R. et al. A double-blind, pla11. cebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res: 1994; 18 1162 1167
14. Mason B. J., Salvato F. R., Williams L. D. et al. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry: 1999; 56 719 724
15. Anton R. F., O'Malley S. S., Ciraulo D. A. et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA: 2006; 95 2003 2017
16. Karhuvaara S., Simojoki K., Virta A. et al. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol Clin Exp Res: 2007; 31 1179 1187
17. Mann K., Bladstrom A. Torup et al. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry: 2013; 73 706 713
18. Gual A., He Y., Torup L. et al. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacology: 2013; 23 1432 1442
19. van den Brink W., Sorensen P., Torup L. et al, for the SENSE Study Group Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study. J Psychopharmacol: 2014; 28 733 744
20. Sobell L. C., Sobell M. B. Timeline follow-back: A technique for assessing self-reported ethanol consumption. In: Litten R. Z. JP A. eds. Measuring Alcohol Consumption: Psychosocial and Biological Methods. Totowa, New Jersey Humana Press: 1992; 41 72
21. Starosta A. N., Leeman R. F., Volpicelli J. R. The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders. J Psychiatr Pract: 2006; 12 80 89
22. van den Brink W., Aubin H. J., Bladstrom A. et al. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol: 2014; 48 570 578
23. Soyka M., Rosner S. Nalmefene for treatment of alcohol dependence. Expert Opin Investig Drugs: 2010; 19 1451 1459
24. Mann K., Lemenager T., Hoffmann S. et al. PREDICT Study Team. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol: 2013; 18 937 946
25. Fleming M. F., Balousek S. L., Grossberg P. M. et al. Brief physician advice for heavy drinking college students: a randomized controlled trial in college health clinics. J Stud Alcohol Drugs: 2010; 71 23 31
26. Anton R. F., Pettinati H., Zweben A. et al. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol: 2004; 24 421 428
27. Salize H. J., Jacke C., Kief S. et al. Treating alcoholism reduces financial burden on care-givers and increases quality-adjusted life years. Addiction (Abingdon, England): 2013; 108 62 70